Overview

Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)

Status:
Withdrawn

Trial end date:
2018-04-20

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and efficacy of the combination of nivolumab plus epacadostat in combination with chemotherapy in first-line recurrent or metastatic patients with squamous cell carcinoma of the head and neck (SCCHN) when compared to the standard of care (EXTREME regimen).

Phase:

Phase 3

Details

Lead Sponsor:

Incyte Corporation

Collaborator:

Bristol-Myers Squibb

Treatments:

Antibodies, Monoclonal
Carboplatin
Cetuximab
Cisplatin
Fluorouracil
Nivolumab